Heart failure & cardiomyopathiesTrial design
Efficacy of perioperative recombinant human brain natriuretic peptide for preventing acute kidney injury after cardiac surgery: Rationale, design, and study protocol for a multicenter, double-blind, randomized controlled trial (PROTECT-CS)
- investigator-initiated, multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-group trial
- study protocol
- 1:1 randomization
Study context
- Population
- High-risk patients undergoing elective on-pump cardiac surgeryplanned randomization
- Participants
- 694 patients
- Planned comparison
- perioperative recombinant human brain natriuretic peptide (rhBNP) with placebo
- Primary endpoint
- Incidence of AKI defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria
- Follow-up
- Within 7 postoperative days
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Secondary endpoints: Acute kidney injury (AKI) severity and duration, renal replacement therapy during the index hospitalization, MAKE-30, MAKE-90, 30-day all-cause mortality, intensive care unit and total length of stay
- planned; no results reported
Original publication
Efficacy of perioperative recombinant human brain natriuretic peptide for preventing acute kidney injury after cardiac surgery: Rationale, design, and study protocol for a multicenter, double-blind, randomized controlled trial (PROTECT-CS). Am Heart J. Published 26 September 2026. doi:10.1016/j.ahj.2026.107615
Summarised from the published abstract; every number is checked against it